These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 29968076)

  • 1. Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.
    Lim SY; Rizos H
    Mamm Genome; 2018 Dec; 29(11-12):866-878. PubMed ID: 29968076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards In Silico Prediction of the Immune-Checkpoint Blockade Response.
    Chen K; Ye H; Lu XJ; Sun B; Liu Q
    Trends Pharmacol Sci; 2017 Dec; 38(12):1041-1051. PubMed ID: 29089139
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventional therapy combined with immune checkpoint inhibitors: Emerging opportunities for cancer treatment in the era of immunotherapy.
    Chang X; Lu X; Guo J; Teng GJ
    Cancer Treat Rev; 2019 Mar; 74():49-60. PubMed ID: 30831375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment].
    Duruisseaux M; Lize-Dufranc C; Badoual C; Bibeau F
    Ann Pathol; 2017 Feb; 37(1):46-54. PubMed ID: 28131419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perspective: cancer vaccines in the era of immune checkpoint blockade.
    Cebon J
    Mamm Genome; 2018 Dec; 29(11-12):703-713. PubMed ID: 30446791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers of response to immune checkpoint blockade in cancer treatment.
    Fujii T; Naing A; Rolfo C; Hajjar J
    Crit Rev Oncol Hematol; 2018 Oct; 130():108-120. PubMed ID: 30196907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
    Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Five new therapies or just one new treatment? A critical look at immune checkpoint inhibition in urothelial cancer.
    Shah AY; Gao J; Siefker-Radtke AO
    Immunotherapy; 2017 Sep; 9(10):781-784. PubMed ID: 28877627
    [No Abstract]   [Full Text] [Related]  

  • 12. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Further knowledge and developments in resistance mechanisms to immune checkpoint inhibitors.
    Berland L; Gabr Z; Chang M; Ilié M; Hofman V; Rignol G; Ghiringhelli F; Mograbi B; Rashidian M; Hofman P
    Front Immunol; 2024; 15():1384121. PubMed ID: 38903504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system.
    Grizzi G; Caccese M; Gkountakos A; Carbognin L; Tortora G; Bria E; Pilotto S
    Expert Rev Mol Diagn; 2017 Dec; 17(12):1055-1069. PubMed ID: 29032709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers of hyperprogression and pseudoprogression with immune checkpoint inhibitor therapy.
    Failing JJ; Dudek OA; Marin Acevedo JA; Chirila RM; Dong H; Markovic SN; Dronca RS
    Future Oncol; 2019 Aug; 15(22):2645-2656. PubMed ID: 31298573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for immunotherapy in urological cancers.
    Gust KM; Resch I; D'Andrea D
    Curr Opin Urol; 2018 Jan; 28(1):25-28. PubMed ID: 29120910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Blockade in Breast Cancer Therapy.
    Bu X; Yao Y; Li X
    Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biomarkers for immune checkpoint inhibitors: The importance of tumor topography and the challenges to cytopathology.
    Clark DP
    Cancer Cytopathol; 2018 Jan; 126(1):11-19. PubMed ID: 29131530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging role of checkpoint inhibition in localized bladder cancer.
    Singh P; Black P
    Urol Oncol; 2016 Dec; 34(12):548-555. PubMed ID: 27776977
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.